Pushing the Boundaries of Partial Nephrectomy beyond T1a Renal Tumors: Does SPARE Nephrometry Score Offer Superior Predictive Value over RENAL and PADUA Nephrometry Scores in Larger Renal Tumors?

Technical Summary: Evaluating the SPARE Nephrometry Score in Complex Partial Nephrectomy

Problem Statement
The management of clinically localized renal tumors has shifted decisively toward nephron-sparing surgery (Partial Nephrectomy, PN) to preserve renal function. While established nephrometry scoring systems like RENAL and PADUA are widely used to quantify tumor complexity, they were primarily validated on small renal masses (T1a, ≤4 cm). As surgical indications expand to include larger, anatomically complex tumors (≥cT1b, cT2, and selected cT3a), the predictive accuracy of these traditional scores for perioperative outcomes and long-term renal function decline remains debated. There is a critical need for preoperative tools that can reliably stratify risk in this increasingly complex patient population and offer superior clinical utility in surgical decision-making.

Methodology
This study conducted a prospective observational analysis of 193 consecutive patients undergoing PN for a single renal mass at a high-volume academic center in Egypt between January 2024 and December 2025. The cohort was specifically enriched with larger tumors, comprising 151 patients (78.2%) with tumors ≥cT1b (including 120 cT1b, 25 cT2a, 1 cT2b, and 5 cT3a).

• Scoring Systems: Preoperative 3T MRI scans were independently reviewed by two uro-radiologists to calculate three nephrometry scores: RENAL, PADUA, and the recently introduced SPARE (Simplified PADUA REnal) score. The SPARE score uniquely incorporates laterality and renal rim involvement as distinct parameters.
• Outcomes: Primary outcomes included high-grade perioperative complications (Clavien-Dindo ≥III) and significant long-term renal function decline (defined as ≥20% reduction in eGFR at 6 months).
• Statistical Analysis: Predictive performance was assessed using Receiver Operating Characteristic (ROC) curve analysis (AUC) and compared via DeLong's test. Crucially, Decision Curve Analysis (DCA) was employed to evaluate the net clinical benefit of each scoring system across a range of threshold probabilities. A multivariable logistic regression model was constructed to develop a predictive nomogram integrating the SPARE score with patient age and ischemia type.

Key Contributions

1. Validation in Complex Cohorts: This is the first study to specifically evaluate the SPARE nephrometry score in a cohort heavily weighted toward larger, complex renal tumors (≥cT1b), directly comparing it against the established RENAL and PADUA systems.
2. Superior Predictive Value for Function: The study demonstrates that the SPARE score offers superior predictive accuracy for long-term renal function decline compared to traditional scores.
3. Clinical Utility Assessment: By utilizing Decision Curve Analysis (DCA), the study moves beyond simple statistical discrimination (AUC) to demonstrate the actual net clinical benefit of using SPARE for surgical planning, particularly in identifying patients at risk for significant eGFR loss.
4. Development of a Predictive Nomogram: The authors constructed and internally validated a nomogram that integrates the SPARE score with clinical parameters (age and ischemia type) to provide a bedside tool for estimating the risk of significant eGFR decline.

Results

• Demographics and Complexity: The median patient age was 51 years. The median tumor size was 5.5 cm. The SPARE score categorized a significantly higher proportion of tumors as "low complexity" (73.6%) compared to RENAL (29.0%) and PADUA (42.0%), indicating a distinct reclassification profile.
• Predictive Accuracy: For predicting significant eGFR decline (≥20% at 6 months), the SPARE score achieved the highest Area Under the Curve (AUC: 0.722), outperforming RENAL (0.716) and PADUA (0.712).
• Decision Curve Analysis: DCA confirmed that the SPARE score yielded the highest net benefit across a clinically relevant range of threshold probabilities (10–50%) for predicting eGFR decline, suggesting it is the most effective tool for preoperative risk stratification in this context.
• Nomogram Performance: The multivariable nomogram, incorporating SPARE score, age, and ischemia type, achieved an AUC of 0.767. The SPARE score was the strongest independent predictor (Odds Ratio: 1.49 per unit increase).
• Functional Outcomes: The study reported 27 patients with high-grade complications (Clavien-Dindo ≥III) and 10 patients with ≥20% eGFR decline. Patients with high-complexity SPARE scores experienced a mean eGFR decline of 19.9%, nearly four times greater than those with low-complexity scores (5.2%). High-grade complications occurred in 14.0% of patients, with a trifecta achievement rate of 85.5%.

Significance and Claims
The paper claims that as the boundaries of partial nephrectomy extend to encompass increasingly complex and locally advanced renal tumors, traditional nephrometry scores may be insufficient for predicting long-term functional outcomes. The study posits that the SPARE score provides superior predictive value for long-term renal function decline and offers a clinically meaningful net benefit in decision-making compared to RENAL and PADUA.

The authors conclude that integrating the SPARE score into routine preoperative imaging assessment, particularly when combined with clinical parameters via the proposed nomogram, may optimize surgical planning and patient counseling in the era of maximal nephron-sparing surgery. They emphasize that while the results are promising, external validation in multi-institutional cohorts is warranted before widespread clinical adoption. The study does not claim the SPARE score replaces existing systems universally but highlights its specific advantage in the challenging subset of patients with larger, complex tumors where preserving renal function is paramount.